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Introduction
In clinical practice, up to 27% of breast cancer (BC) patients receive neoadjuvant chemotherapy (NAC). In this context, a pathological complete
response (pCR) is the most commonly used end-point. High pCR rate is frequently associated with tumor infiltrating lymphocytes. Besides,
circulating immune cells are also often linked to chemotherapy response.
Materials and methods
We performed a retrospective analysis on 112 BC patients (79 triple negative, 33 HR-/HER2+), treated with standard NAC. The median follow-up
was 37.5 months (range 9-156). Eosinophil and lymphocyte count were collected at baseline, after surgery, at 1 year of follow-up and at relapse.
The primary end-point is the association between the relative eosinophil count (REC) and pCR. The secondary end-points are the associations of
REC, relative lymphocyte count (RLC) and eosinophil-lymphocyte product (ELP) with relapse, disease free (DFS) and breast cancer specific (BCSS)
survival and to study the variation of REC and RLC during follow-up.
Results
We observed a higher pCR rate in patients with
REC≥1.5% vs patients with REC <1.5% (55.6% vs 36.2%, p
= 0.04), and a higher median REC in patients with pCR
(1.9% vs 1.2%, p 0.048). No statistically significant
associations were detected between REC and relapse,
nor between RLC with pCR or relapse. We observed a 3-
year BCSS of 91% vs 80% for high and low REC
respectively (p 0.05; HR 0.336, 95% CI 0.107-1.058) and
of 88% vs 49% in RLC≥17.5% and <17.5% respectively (p
0.01; HR 0.217, 95% CI 0.060-0.783). No significant
differences were detected for DFS. Combining the two
parameters in the ELP, we observed an association with
pCR (59.6% in ELP≥35.8 vs 30.9% in ELP<35.8, p 0.002),
relapse (12.3% vs 29.1% in high and low ELP, p 0.028),
DFS (3-year DFS 90% vs 69% in high and low ELP, p 0.012;
HR 0.337, 95% CI 0.138-0.823) and BCSS (3-year BCSS
95% vs 75% in high and low ELP, p 0.001; HR 0.129, 95%
CI 0.029-0.573). Moreover, we observed a raise of REC
after surgery from 1.4% to 2.7% (p 0.0001) and a
significant reduction at relapse from 2.8% to 1.7% (p
0.021). Conversely, a reduction of RLC from 26.75% at
baseline to 20.15% after surgery (p 0.0001), without
significant variation at relapse, was detected.
Conclusion
REC, RLC and ELP could be new promising, affordable and
accessible biomarkers predictive for NAC response and
prognostic for longer survival in TNBC and HR-/HER2+ BC.
Confirmation in a larger cohort is needed.
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A. Median baseline REC: 1.9% in
patients experiencing a pCR vs
1.2% in patients without pCR
(p=0.048). B. Median baseline
RLC: 28.1% vs 26.9%,
respectively (p=0.184).
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Scatter dot plots for REC and RLC after surgery, after 1 year of follow-up and at relapse.
A. Baseline REC in the whole cohort: median value 1.4% at baseline vs 2.7% after surgery and 2.5%
after 1 year of follow-up. B. Baseline REC in 23 patients experiencing a relapse: median value 1.4% at
baseline vs 2.8% after surgery and 1.7% at relapse C. Baseline RLC in the whole cohort: 26.75% at
baseline vs 20.15% after surgery and 24.90% after 1 year of follow-up. D. Baseline RLC in 23 patients
experiencing a relapse: 23.3% at baseline vs 19.7% after surgery and 17% at relapse. The significant
corresponding p values were reported in each panel. ***=pval≤0.0001; **=pval≤0.001.
